One of the major problems encountered by Polish scientists working in the drug discovery field in Poland, is a shortage of business partners capable of conducting preclinical development phase. Since only few companies in Poland are working on innovative therapies, the interaction between the academia and industry should be identified as a bottleneck of Polish ingenious drug development and marketing. Therefore companies that bridge the progression in the pipeline using a value-added approach are urgently needed in the Polish medical biotechnology area.
    The first company in Poland specialized in preclinical drug development is Selvita. Our mission is to create a multidisciplinary platform which provides wide range of possibilities necessary to translate innovative discoveries into preclinical candidates with high chances of becoming marketed in the future. Expert-based evaluation of the project, decrease in the attrition rates through smart in silico target and compound selections, enriched by a wide range of in vitro and in vivo assays performed by our company are the key features allowing us to focus on the rapid and successful advancement of a drug candidate in the pipeline. This presentation provides comprehensive information about Selvita’s novel approach in the field of Polish medical biotechnology and our integrated procedure of modern therapeutics development.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/14674 must be provided.

1. SEL-120-small molecule CDK8/9 kinase inhibitors as potential targeted therapy in colorectal cancer treatment.
2. In vitro and in vivo evaluation of novel Pim kinase inhibitors with potent anticancer activity